Publicly reported Fournier’s gangrene lawsuit settlement amounts range from about $450,000 to $6.25 million, and every one of those figures comes from a medical malpractice case alleging a missed or delayed diagnosis. The parallel wave of product liability cases against makers of SGLT2 inhibitor diabetes drugs has produced no reported settlements or verdicts. Many malpractice settlements are also confidential, so these public numbers show the shape of the market rather than a complete picture.
Reported Malpractice Settlements and Verdicts
The disclosed outcomes span a wide range because the injuries themselves do. Death cases, permanent disability, and loss of genital tissue drive the highest numbers; cases where the patient survived with extensive but reconstructable damage sit lower.
- $6.25 million settlement. A woman was prematurely discharged from a hospital in November 2019 despite an elevated white blood cell count. She returned two days later, was diagnosed with Fournier’s gangrene and necrotizing fasciitis, and suffered septic shock, a spinal cord infarct, and permanent disability.1Duffy & Duffy. $6,250,000 Settlement for a Negligent Premature Discharge
- $1.53 million jury verdict, reduced to about $763,000. A 38-year-old man in Maryland presented with a painful cyst near his perineum. A CT scan showed air in the scrotal sac, but doctors diagnosed cellulitis. Surgery did not happen until more than 58 hours after the scan, and he lost his scrotal sac, right testicle, and part of his penis. The jury awarded roughly $1.53 million; a state cap on non-economic damages cut the payout to about $763,000.2Miller & Zois. Necrotizing Fasciitis Misdiagnosis Claims in Maryland3Clinician. Failure to Diagnose Necrotizing Fasciitis Yields $1.53 Million Jury Verdict
- $1 million settlement. A 58-year-old Massachusetts man died from sepsis secondary to Fournier’s gangrene after urgent care and emergency department staff misdiagnosed him with gout. He was sent home with foot pain and fever, returned with necrotic scrotal tissue, and died the same day despite emergency surgery. The case settled before trial in Hampden Superior Court in Springfield.4Lubin & Meyer. Necrotizing Fasciitis Malpractice
- $950,000 settlement (California, 2019). A woman developed perineal necrotizing fasciitis after childbirth, suffered septic shock and multi-organ failure, and died five days later. Her family alleged the hospital failed to diagnose the condition in time.2Miller & Zois. Necrotizing Fasciitis Misdiagnosis Claims in Maryland
- $450,000 jury verdict. A patient in Fredericksburg, Virginia was discharged after initial treatment for a peri-rectal abscess and returned days later with Fournier’s gangrene. He needed emergency debridement and eight additional surgeries at Walter Reed, including scrotal flaps, a colostomy, skin grafts, and hernia repairs.5Virginia Lawyers Weekly. Plaintiff Wins $450K Verdict After Infection Turns to Gangrene
Two additional malpractice cases had documented medical bills exceeding $244,000 and $276,000. Both settled for confidential amounts.6Reis Kirkland. Fournier’s Gangrene The pattern is consistent: medical costs alone typically run into the hundreds of thousands before any pain-and-suffering component is added.
What Drives the Dollar Amount
Four factors do most of the work in setting a Fournier’s gangrene case value.
Severity of injury. Death, permanent disability, organ loss, and disfigurement push cases toward the top of the range. The $6.25 million settlement involved a spinal cord infarct and permanent disability; the $450,000 verdict involved extensive but survivable surgery. Cases with loss of genital tissue tend to attract substantial non-economic damages.
Documented medical expenses. Even non-fatal cases regularly show bills between $200,000 and $300,000 or more. In the Maryland case, the jury awarded roughly $122,000 in medical expenses, and nearly all of the remaining $1.4 million came from non-economic damages for pain, suffering, and disfigurement.3Clinician. Failure to Diagnose Necrotizing Fasciitis Yields $1.53 Million Jury Verdict
Strength of causation evidence. Plaintiffs must show that an earlier diagnosis would have produced a better outcome, not just that a diagnosis was late. In a Kansas malpractice case, the plaintiff’s own expert acknowledged the delay caused “additional tissue loss” but could not say how much of the damage came from the delay versus the natural progression of the infection. The trial court granted summary judgment for the defendants, and the Kansas Court of Appeals affirmed in 2021.7Kansas Courts. Bowens v. Greenwood County Hospital A shaky causation theory can end a sympathetic case before a jury ever sees it.
State damage caps. Some states cap non-economic damages in medical malpractice cases. In the Maryland verdict, the cap cut the plaintiff’s recovery from about $1.53 million to about $763,000, roughly in half.3Clinician. Failure to Diagnose Necrotizing Fasciitis Yields $1.53 Million Jury Verdict Where the injury happened matters as much as how bad it was.
The SGLT2 Inhibitor Drug Lawsuits
A separate line of cases targets the makers of SGLT2 inhibitor diabetes drugs, which the FDA linked to Fournier’s gangrene in an August 2018 safety communication. The agency required Fournier’s gangrene warnings to be added to canagliflozin (Invokana, Invokamet), dapagliflozin (Farxiga), empagliflozin (Jardiance, Synjardy, Glyxambi), and ertugliflozin (Steglatro).8Medscape. SGLT2 Inhibitors: Reports of Fournier’s Gangrene Plaintiffs allege the manufacturers marketed these drugs without adequate warnings until the FDA forced the label change.9AboutLawsuits.com. Farxiga Fournier’s Gangrene Lawsuit
For a searcher trying to gauge case value, the important fact is this: no public settlements or jury verdicts exist in any SGLT2 inhibitor Fournier’s gangrene case. The Invokana multidistrict litigation (MDL No. 2750) was closed in April 2023 after 1,208 cases were resolved. The Farxiga MDL (No. 2776) was terminated in 2020. Neither produced any reported verdict or settlement figure.10Drugwatch. SGLT2 Inhibitors Lawsuits Jardiance claims are not in a formal MDL; they are proceeding as individual lawsuits in a mass tort framework, reportedly in active discovery as of mid-2026.11LawFold. Jardiance Lawsuit
Legal analysts have projected settlement values for Fournier’s gangrene drug cases involving surgical intervention at $250,000 to over $1.5 million per plaintiff. Those numbers are estimates based on comparisons to other pharmaceutical mass torts, not on actual outcomes in these cases.11LawFold. Jardiance Lawsuit Whether they hold up depends on how bellwether trials in the Jardiance litigation go, and on whether defendants can persuade juries that underlying diabetes and other risk factors, rather than the drug, caused the infection. That causation fight is a large part of why no drug case has yet reached a jury.